Here’s a wrap of the main tech-related coronavirus news in the last 24 hours

Much of the world is waking up to a strange new reality. As the coronavirus strain, COVID-19, swept across the planet, today may go down in history as the day when huge numbers of countries were largely united in a global shut-down to address the pandemic.

TechCrunch brings you a wrap of the technology world’s response to the virus so far in our own dedicated COVID-19 coverage.

• In Extra Crunch we cover how you should pitch a story in the era of COVID-19.

• Google says coronavirus has become its biggest search topic by a country mile this year, and to continue its efforts to harness that attention in the best possible way, late on Friday the company launched a new information portal dedicated to the pandemic as well as an improved search experience for desktop and mobile.

• In response to COVID-19, Hulu has added a free live news stream to its on-demand app for customers who only subscribe to its on-demand service, not its live TV add-on. The news coverage is provided in partnership with ABC News Live, and brings live news 24/7 to Hulu on-demand subscribers as part of their existing subscription.

• Unfortunately, “Robocalls”, which have been targeting the vulnerable and unsuspecting for years, are taking advantage of the current global catastrophe to enhance their scams. The FCC warns that it has received numerous reports of coronavirus-related robocall cons in the wild — here’s what to look for.

• Two major tech companies — Amazon and IBM — have each announced programs to encourage developers to find solutions to a variety of problems related to the pandemic.

• Google announced on Twitter that it is cancelling its annual I/O developer conference out of concern for the health and safety of all involved. It will not be holding any online conference in its place either.

• Rivian, the buzzy electric vehicle startup that is backed by Amazon and Ford, is shutting down all of its facilities due to the spread of COVID-19, the disease caused by coronavirus. Rivian employs more than 2,000 workers across several locations, including its headquarters in Plymouth, Mich., a factory in Normal, Ill. as well as operations in San Jose and Irvine, Calif., where engineers are working on autonomous vehicle technology. Rivian also has an office in the U.K.

• During two of this week’s White House briefings, President Trump referred specifically to two potential treatments that have been identified by medical researchers and clinicians. But no drugs or treatments have been proven as effective for either the prevention of contracting COVID-19 or for its treatment. While chloroquine has been used for decades to treat malaria, and chronic rheumatoid arthritis, it can have dangerous side effects, including death, if taken incorrectly. Even when taken correctly, it can cause things like stomach distress and even permanent damage to a person’s vision.

• The COVID-19 outbreak isn’t just affecting movie theaters — it has also halted TV and film production around the world. For Netflix, that has included production on high-profile titles like “The Witcher” and “Stranger Things.” So the streaming company just announced that it has created a $100 million fund that it says will support the cast and crew who have suddenly found themselves out of work.

• Elon Musk tweeted Friday that Tesla and SpaceX employees are “working on ventilators” even though he doesn’t believe they will be needed. His confirmation on Twitter that both of the companies he leads are working on ventilators comes a day after New York City Mayor Bill de Blasio made a direct plea to Musk to help alleviate a shortage at hospitals gearing up to combat COVID-19.

• Uber Eats is waiving delivery and activation fees in the UK to support restaurants hit by decreasing demand during the coronavirus crisis. The measure will apply until March 31 when it says it will review it. On Monday the on-demand food delivery giant announced a similar waiver of delivery fees in the US. The announcement by Uber Eats UK comes shortly after Just Eat UK said it would reduce its commission and waive some fees for 30 days — as part of an emergency support package for partner restaurants struggling to cope with disruption to their businesses.

• Privacy-hostile practices by tech giants face ongoing legislative challenges, but a pandemic is clearly an exceptional circumstance. These days, governments are now turning to the tech sector for help. US President Donald Trump was reported last week to have summoned a number of tech companies to the White House to discuss how mobile location data could be used for tracking citizens. And in another development this month he announced Google was working on a nationwide coronavirus screening site — in fact it’s Verily, a different division of Alphabet. But concerns were quickly raised that the site requires users to sign in with a Google account, suggesting users’ health-related queries could be linked to other online activity the tech giant monetizes via ads.

• Diligent Robotics wants to give nurses a helper droid that can run errands for them around the hospital. The startup’s bot Moxi is equipped with a flexible arm, gripper hand and full mobility so it can hunt down lightweight medical resources, navigate a clinic’s hallways and drop them off for the nurse. With the world facing a critical shortage of medical care professionals, Moxi could help healthcare centers use their staff as efficiently as possible. And because robots can’t be infected by COVID-19, they’re one less potential carrier interacting with vulnerable populations.

In other news from around the web:

• The Telegram app emerged a few years ago as a challenger to WhatsApp and took off largely in non-Western countries. A story today in the China Tech site Abacus explores how Telegram is emerging as an alternative source of news form outside China ‘Great Firewall’, and is being accessed by citizens there who are hungry for uncensored news about the COVID-19 pandemic. The “2019-nCoV outbreak real-time broadcast,” channel now has more than 87,000 subscribers, with recent messages getting between 15,000 and 20,000 views, according to Telegram channel’s view counter.

• Another report today in The Verge explores how Amazon workers across the US and in many other countries are finding themselves designated as “key workers” who must continue to show up to deliver goods nations, like the US, which have gone into an effective quarantine. However, many of those workers are concerned that safety precautions, benefits, and protections have not changed sufficiently to reflect the new reality of living and working in a pandemic, and that even Amazon warehouses that keep operating as everything else shuts down many workers there are of course likely to contract the virus.

• Getaround is a startup that actually launched at TechCrunch Disrupt several years ago, and the car-sharing company has soared in distribution and valuation in the last few years. But with the coronavirus outbreak suddenly affecting people unwilling or unable to share a personal car that might well be owned by someone infected by the virus, Getaround is now experiencing a huge plunge in demand. As a result, the company is now, according to Bloomberg. reportedly seeking a sale after finding itself “dangerously short on cash”, according to people familiar with the matter.

• Over at Microsoft, the tech giant is now offering its Healthcare Bot service to organizations on the frontlines of the COVID-19 response to help screen patients for potential infection and care. As an example, the CDC just released a COVID-19 assessment bot that can quickly assess the symptoms and risk factors for people worried about infection, provide information and suggest the next course of action such as contacting a medical provider or, for those who do not need in-person medical care, managing the illness safely at home.

The news is significant because several healthcare startups such as Babylon Health and Ada Health already offer such AI-powered ‘chat’ apps which many will likely be turning to in this crisis.


Source: Tech Crunch

Original Content podcast: Apple’s ‘Amazing Stories’ is thoroughly unamazing

It’s been two-and-a-half years since the news first broke that Steven Spielberg would be rebooting his ’80s anthology series “Amazing Stories” for Apple’s then-unnamed streaming service.

Now, after some behind-the-scenes drama, “Amazing Stories” has launched on Apple TV+, with the first two segments currently available. The first, “The Cellar,” is a time travel romance, while “The Heat” is a combination ghost story/murder mystery/sports drama.

As we explain on the latest episode of the Original Content podcast, it’s hard to tell exactly who this show was made for. Both of the episodes aired so far get pretty goofy, as if the show was made for kids — but they also move into surprisingly dark territory. Both start with familiar setups, then take some surprising twists and turns, but the results aren’t very satisfying.

In the end, it was hard for any of us to muster any enthusiasm for watching the show’s remaining three episodes.

You can listen to our full review in the player below, subscribe using Apple Podcasts or find us in your podcast player of choice. If you like the show, please let us know by leaving a review on Apple . You can also send us feedback directly. (Or suggest shows and movies for us to review!)

And if you’d like to skip ahead, here’s how the episode breaks down:

0:00 Intro
0:44 “Amazing Stories” review
25:50 “Amazing Stories” spoiler discussion


Source: Tech Crunch

WhatsApp tests new feature to fight misinformation: Search the web

WhatsApp, one of the most popular instant messaging platforms on the planet, is testing a feature that could make it simpler for its 2 billion users to tell whether the assertion made in messages they have received is true.

In the recent most beta version of its Android app, the Facebook-owned service has given users the ability to quickly comb through the web with the text or video they have received for more context.

WhatsApp has been testing this feature in some capacity for several quarters now (last year, it allowed some users to look up an image on the web), but a spokesperson has now told TechCrunch that the platform plans to roll out this feature in the near future.

“We are working on new features to help empower users to find out more information about the messages they receive that have been forwarded many times. This feature is currently in testing, and we look forward to rolling it out in the near future,” a spokesperson said in a statement.

Images credit: @shrinivassg

The timely test of this feature comes at a time when WhatsApp and other messaging platforms are being used more often than ever before as people stay in touch with their friends, families, and colleagues in the face of a global pandemic.

And as it has happened in the past, several platforms including WhatsApp are grappling with spread of misinformation — this time about the coronavirus.

But WhatsApp has moved to take action much swiftly this time. It began reaching out to dozens of governments last month to assist in their efforts to provide accurate information to the general public, it said today.

Earlier today, India announced a WhatsApp bot to help its citizens be better informed about coronavirus. Earlier this week, the World Health Organization also announced a WhatsApp bot for people globally to bust myths about the coronavirus and answer some of the most frequently asked questions about the disease.

“The WHO Health Alert is the latest official NGO or government helpline to become available on WhatsApp, joining the Singapore Government, The Israel Ministry of Health, the South Africa Department of Health, and KOMINFO Indonesia. We are actively working to launch local services with other countries as well,” WhatsApp said in a statement.


Source: Tech Crunch

Hydroxychloroquine, chloroquine and other potential COVID-19 treatments explained

During two of this week’s White House briefings, President Trump referred specifically to two potential treatments that have been identified by medical researchers and clinicians, and that have undergone various degrees of investigation and testing in the ongoing fight against the global coronavirus pandemic. It’s important to note upfront that regardless of what you may have heard, from Trump or any other sources, no drugs or treatments have been proven as effective for either the prevention of contracting COVID-19, or for its treatment.

That said, a number of different clinical studies are currently in progress all over the world, and in the U.S., the National Institutes of Health is looking to fill a 400-volunteer study that will provide clinical results related to use of remdesivir, an antiviral drug developed by Gilead originally as a treatment for Ebola, but it’s still only in clinical trials even for treatment of that disease. This study could also add in other drug candidates as additional test therapies. Meanwhile, studies in China and France have examined the effectiveness of anti-malarial drugs including chloroquine and hydroxychloroquine – including one small-scale study that suggests the positive effects of hydroxycholoroquine in reducing both the duration and symptoms of COVID-19 in combination with an antibiotic called azithromycin.

The important thing to keep in mind when considering these or any other potential treatments for the novel coronavirus, which is still relatively young, is that a lot of what we know about them so far is effectively anecdotal, and based not on the kind of scientifically rigours controlled clinical studies that are normally used in the years-long development and certification of drugs. Instead, treatments like remdesivir and chloroquine/hydroxychloroquine are being deployed in the field by healthcare practitioners based on their approved use in similar (but crucially not the same) situations, like the Ebola and SARS outbreaks.

Often, they’re being used under what’s called ‘compassionate’ grounds in the U.S. This effectively amounts to employing a drug that’s not yet certified for general use in treatment of a patient whose condition is so severe that a doctor is willing to go to desperate lengths to try to alleviate their symptoms. This has the advantage of sidestepping typical testing and approval procedures, and requiring that the results of its use are documented, which contributes to the overall body of clinical knowledge in terms of its effects and interactions with patients and with COVID-19.

It’s not a clinical study, however, and that means there are still a lot of unknowns when it comes to its use that just can’t be learned or asserted based on scattered, individual instances of compassionate care treatment.

“As the Commissioner of FDA and the President mentioned yesterday, we’re trying to strike a balance between making something with the potential of an effect available to the American people, at the same time that we do it under the auspices of a protocol that would give us information to determine if it’s truly safe and truly effective,” explained National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci during a press conference on Friday. “But the information that you’re referring to specifically is anecdotal, it was not done in a controlled clinical trial. So you really can’t make any definitive statement about it.”

During Thursday’s White House coronavirus pandemic task force briefing, Trump made false claims that chloroquine was already approved by the FDA as a treatment for COVID-19 under an emergency authorization. FDA Director Dr. Stephen Hahn clarified that this and remdesivir were being considered and studied by the FDA, as was an approach that would use plasma extracted from patients who’d recovered from COVID-19 as a potential source of antibodies for others. Still, all of these are still quite far away from clinical deployment in any generally approved way.

Meanwhile, Fauci’s cautions should be taken for what they are: Warnings that are primarily meant to emphasize that the reasons the FDA requires clinical studies, even for drugs already tentatively approved for use in other cases, is because it has patient health and safety in mind. While chloroquine has been used for decades to treat malaria, and chronic rheumatoid arthritis, it can have dangerous side effects, including death, if taken incorrectly. Even when taken correctly, it can cause things like stomach distress, and even permanent damage to a person’s vision.

Fauci’s comments Friday explain the risks of putting too much stock in any potential treatment at this stage, even if they are showing promising results among small or even medium-sized deployments.

“You’ve got to be careful when you say fairly effective, it was never done in a clinical trial that compared it to anything,” he said in answer to a reporter’s question about chloroquine’s efficacy in treating SARS. “It was given to individuals and felt that maybe it worked […] Whenever you do a clinical trial, you do standard of care, versus standard of care plus the agent you’re evaluating. That’s the reason why we showed back in Ebola why particular interventions worked.”

A summary survey of various prospective treatments and their current status was published today In Medscape, and this includes the current state of remdesivir and chloroquine investigations, as well as a number of other drugs being studied by researchers. As has been reported here and elsewhere, there are promising signs that they could prove effective in either treatment, or treatment and even preventative use (in the case of remedesivir), but these are, as Dr. Fauci puts it, only the first step that should lead to more sophisticated clinical studies, which themselves will then need competing peer studies to eventually prove out.


Source: Tech Crunch

Netflix announces $100M relief fund after TV and film production halted

When it comes to the entertainment industry, the COVID-19 outbreak isn’t just affecting movie theaters – it’s also halted TV and film production around the world. For Netflix, that’s included production on high-profile titles like “The Witcher” and “Stranger Things.”

So the streaming company just announced that has created a $100 million fund that it says will support the cast and crew who have suddenly found themselves out of work.

In the announcement, Netflix Chief Creative Ted Sarandos said that there are now “hundreds of thousands of cast and crew without jobs,” including “electricians, carpenters and drivers, many of whom are paid hourly wages and work on a project-to-project basis.”

He said that most of this money will go to “the hardest hit workers on our own productions around the world” — though it sounds like the company is still figuring out exactly what form that support will take. (Sarandos noted that Netflix is already providing two weeks pay to the productions suspended last week.)

In addition, Sarandos said $15 million will go to “third parties and non-profits providing emergency relief to out-of-work crew and cast in the countries where we have a large production base.”

In the United States, that includes $1 million each to the SAG-AFTRA Covid-19 Disaster Fund, the Motion Picture and Television Fund and the Actors Fund Emergency Assistance. In Canada, that includes $1 million that will be split between the AFC and Fondation des Artistes. Elsewhere, Sarandos said Netflix is “working with existing industry organizations to create similar creative community emergency relief efforts.”


Source: Tech Crunch

FluSense system tracks sickness trends by autonomously monitoring public spaces

One of the obstacles to accurately estimating the prevalence of sickness in the general population is that most of our data comes from hospitals, not the 99.9 percent of the world that isn’t hospitals. FluSense is an autonomous, privacy-respecting system that counts the people and coughs in public spaces to keep health authorities informed.

Every year has a flu and cold season, of course, though this year’s is of course far more dire. But it’s like an ordinary flu season in that the main way anyone estimates how many people are sick is by analyzing stats from hospitals and clinics. Patients reporting “influenza-like illness” or certain symptoms get aggregated and tracked centrally. But what about the many folks who just stay home, or go to work sick?

We don’t know what we don’t know here, and that makes estimates of sickness trends — which inform things like vaccine production and hospital staffing — less reliable than they could be. Not only that, but it likely produces biases: Who is less likely to go to a hospital, and more likely to have to work sick? Folks with low incomes and no healthcare.

Researchers at the University of Massachusetts Amherst are attempting to alleviate this data problem with an automated system they call FluSense, which monitors public spaces, counting the people in them and listening for coughing. A few of these strategically placed in a city could give a great deal of valuable data and insight into flu-like illness in the general population.

Tauhidur Rahman and Forsad Al Hossain describe the system in a recent paper published in an ACM journal. FluSense basically consists of a thermal camera, a microphone, and a compact computing system loaded with a machine learning model trained to detect people and the sounds of coughing.

To be clear at the outset, this isn’t recording or recognizing individual faces; Like a camera doing face detection in order to set focus, this system only sees that a face and body exists and uses that to create a count of people in view. The number of coughs detected is compared to the number of people, and a few other metrics like sneezes and amount of speech, to produce a sort of sickness index — think of it as coughs per person per minute.

A sample setup, above, the FluSense prototype hardware, center, and sample output from the thermal camera with individuals being counted and outlined.

Sure, it’s a relatively simple measurement, but there’s nothing like this out there, even in places like clinic waiting rooms where sick people congregate; Admissions staff aren’t keeping a running tally of coughs for daily reporting. One can imagine not only characterizing the types of coughs, but visual markers like how closely packed people are, and location information like sickness indicators in one part of a city versus another.

“We believe that FluSense has the potential to expand the arsenal of health surveillance tools used to forecast seasonal flu and other viral respiratory outbreaks, such as the COVID-19 pandemic or SARS,” Rahman told TechCrunch. “By understanding the ebb and flow of the symptoms dynamics across different locations, we can have a better understanding of the severity of a novel infectious disease and that way we can enforce targeted public health intervention such as social distancing or vaccination.”

Obviously privacy is an important consideration with something like this, and Rahman explained that was partly why they decided to build their own hardware, since as some may have realized already, this is a system that’s possible (though not trivial) to integrate into existing camera systems.

“The researchers canvassed opinions from clinical care staff and the university ethical review committee to ensure the sensor platform was acceptable and well-aligned with patient protection considerations,” he said. “All persons discussed major hesitations about collection any high-resolution visual imagery in patient areas.”

Similarly, the speech classifier was built specifically to not retain any speech data beyond that someone spoke — can’t leak sensitive data if you never collect any.

The plan for now is to deploy FluSense “in several large public spaces,” one presumes on the UMass campus in order to diversify their data. “We are also looking for funding to run a large-scale multi-city trial,” Rahman said.

In time this could be integrated with other first- and second-hand metrics used in forecasting flu cases. It may not be in time to help much with controlling COVID-19, but it could very well help health authorities plan better for the next flu season, something that could potentially save lives.


Source: Tech Crunch

SpaceX and Tesla are ‘working on’ ventilators, Elon Musk says

Elon Musk tweeted Friday that Tesla and SpaceX employees are “working on ventilators” even though he doesn’t believe they will be needed.

His confirmation on Twitter that both of the companies he leads are working on ventilators comes a day after New York City Mayor Bill de Blasio  made a direct plea to Musk to help alleviate a shortage at hospitals gearing up to combat COVID-19.

It’s unclear how many employees are working on the ventilators and which Tesla factory — it could be Buffalo, New York, Fremont, Calif., Sparks, Nevada or even Shanghai — has dedicated space to the project. The SpaceX facility is located in Hawthorne, Calif.

Musk didn’t describe what capacity would be or how long it might take to scale up such an endeavor.  One Twitter follower recommended building one large ventilator with multiple branches and lines. Musk noted that a single computer, pump and pressure accumulator could do the job, but noted that individual valves per patient would be ideal.

Whatever Musk decides, his project still faces specific obstacles. Certified medical personnel will need to be involved in such an operation and ventilator hardware used in clinical settings still must be approved by the FDA, which could delay production.

Still, the need for ventilators is urgent, prompting other automakers to investigate ways of ramping up production. GM, Volkswagen and Ford have all reportedly either talked to the White House or committed to looking at the problem. Volkswagen said Friday it has created a task force to look into using 3D printing to make hospital ventilators.

De Blasio tweeted out his plea to Musk Thursday morning. “Our country is facing a drastic shortage and we need ventilators ASAP — we will need thousands in this city over the next few weeks. We’re getting them as fast as we can but we could use your help!”

The mayor’s office has reached out to the person who runs Musk’s family office, his communications director and his lobbyist, press secretary Freddi Goldstein told TechCrunch  in an email. “Given his response on Twitter, we’re hopeful he will be able to help,” Goldstein added

The COVID-19 pandemic had elicited a seemingly conflicting mix of responses from Musk. He has downplayed COVID-19 in emails to employees and on social media. In one companywide email sent to SpaceX employees, Musk wrote that they have a higher risk of being killed in a car crash than dying from the coronavirus, BuzzFeed reported last week.

Since then, Musk wrestled with officials in Alameda County to keep Tesla’s Fremont, Calif., factory open in spite of a government directive to close all non-essential businesses. Tesla announced Thursday plans to suspend production there beginning March 23.

Some basic operations that would support Tesla’s  charging infrastructure and what it describes as its “vehicle and energy services operations” will continue at the factory, which under normal circumstances employs more than 10,000 people. Tesla is also suspending operations at its factory in Buffalo, N.Y., except for “those parts and supplies necessary for service, infrastructure and critical supply chains,” the company said in a statement.

Musk has jumped into crises before with mixed results. In 2018, Musk and the Musk Foundation donated $480,350 to add ultraviolet water filtration systems and water stations to all 12 area schools in Flint, Michigan. The effort was delayed but eventually the systems were installed, beginning in fall 2019.

In 2018, he put SpaceX engineers to work on a pod that could be used to save children trapped in a flooded cave in Thailand. Rescuers didn’t use the device and an argument with a cave diving expert that played out on social media and national television led to a defamation lawsuit, after Musk repeatedly called him ‘pedo guy.’ Musk was found not liable for defamation in a federal court in 2019.

 


Source: Tech Crunch

Hospital droid Diligent Robotics raises $10M to assist nurses

28% of a nurse’s time is wasted on low-skilled tasks like fetching medical tools. We need them focused on the complex and compassionate work of treating patients, especially amid the coronavirus outbreak. Diligent Robotics wants to give them a helper droid that can run errands for them around the hospital. The startup’s bot Moxi is equipped with a flexible arm, gripper hand, and full mobility so it can hunt down lightweight medical resources, navigate a clinic’s hallways, and drop them off for the nurse.

With the world facing a critical shortage of medical care professionals, Moxi could help health care centers use their staffs as efficiently as possible. And since robots can’t be infected by COVID-19, they’re one less potential carrier interacting with vulnerable populations.

Today, Diligent Robotics announces its $10 million Series A that will help it scale up to deliver “more robots to more hospitals” CEO Andrea Thomaz tells me. “We’ve been designing our product, Moxi, side by side with hospital customers because we don’t just want to give them an automation solution for their materials management problems. We want to give them a robot that frontline staff are delighted to work with and feels like a part of the team.”

The round led by DNX Ventures brings Diligent Robotics to $15.75 million in total funding that’s propelled it to the fifth generation of its Moxi robot. It currently has two deployed in Dallas, TX but is already working with two of the three top hospital networks in the U.S. ““As the current pandemic and circumstance has shown, the real heroes are our healthcare providers” says Q Motiwala, partner at DNX Ventures. The new cash from DNX, True Ventures, Ubiquity Ventures, Next Coast Ventures, Grit Ventures, E14 Fund, and Promus Ventures will help Diligent Robotics expand Moxi’s use cases and seamlessly complement nurses’ workflows to help alleviate the talent crunch.

Thomaz came up with the idea for a hospital droid after doing her Ph.D. in social robotics at the MIT Media lab. Her co-founder and CTO Vivian Chu had done a masters at UPenn on how to give robots a sense of touch, and then came to work with Thomaz at Georgia Tech. They were inspired by a study revealing how nurses spent so much time acting as hosptial gofers, so in 2016 they applied for and won a National Science Foundation grant of $750,000 that funded a six-month sprint to build a prototype of Moxi.

Since then, 18-person Diligent Robotics has worked with hundreds of nurses to learn about exactly what they need from an autonomous assistant.Today you will go about your day, and you probably won’t interact with any robots….we want to change that” Thomaz tells me. “The only way you can really bring robots out of the warehouses, off of the factory floors, is to build a robot that can work in our dynamic and messy everyday human environments.” The startup’s intention isn’t to full replace humans, which it doesn’t think is possible, but to let them focus on the most human elements of their jobs.

Moxi is about the size of a human but designed to look like an 80s movie robot so as not to engender and uncanny valley cyborg weirdness. Its head and eyes can move to signal intent, like which direction it’s about to move in, while sounds let it communicate with nurses and acknowledge their commands. A moving pillar lets it adjust its height while its gripper hand and arm can pick and put down smaller pieces of hospital equipment. Its round shape and courteous navigation makes sure it can politely share crowded hallways and travel via elevator.

Diligent Robotics’ solution engineers work with hospitals to teach Moxi how to get around and what they need. The company hopes to eventually build the ability to learn and adapt right into the bot so nurses can teach it new tasks on the fly. “The team continues to demonstrate unmatched robotics-specific innovation by combining social intelligence and human-guided learning capabilities” says True Ventures partner and Diligent board member Rohit Sharma.

Hospitals pay an upfront fee to buy Moxi robots, and then there’s a monthly fee for the software, services, and maintenance. Thomaz admits that “Hospitals are naturally risk-averse, and can be wary to take up new technology” so the startup is taking a slow and steady approach to deployment so it can convince buyers that Moxi is worth the learning curve.

Diligent Robotics will be competing with companies like Aethon’s TUG bot for pulling laundry and pharmacy carts. Other players in the hospital tech space include Xenex’s machine that disinfects rooms with light, and surgical bots like those from Johnson & Johnson’s Auris and Intuitive Surgical.

Diligent Robotics hopes to differentiate itself by building social intelligence into Moxi so it feels more like an intern than a gadget. “Time again, we hear from our hospital partners that Moxi not only returns time back to their day but also brings a smile to their face” says Thomaz. The company wants to evolve Moxi for other dull, dirty, or dangerous service jobs.

Eventually, Diligent Robotics hopes to bring Moxi into people’s homes. “While we don’t see robots replacing the companionship and the human connection, we do dream of a time that robots could making nursing homes more pleasant by offsetting the often staggering numbers of caretakers to bed ratios (as bad as 30:1)” Thomaz concludes. That way, Moxi could “help people age with dignity and hold onto their independence for as long as possible.”


Source: Tech Crunch

US State Department issues unprecedented ‘do not travel’ warning over coronavirus

The U.S. State Department has issued an unprecedented “do not travel” warning to U.S. citizens, as the number of coronavirus-related infections jumped sharply overnight.

The advisory said U.S. citizens should “avoid all international travel due to the global impact of COVID-19,” the coronavirus strain which last week was declared a global pandemic. The advisory added that citizens abroad should “arrange for immediate return” unless they are prepared to stay overseas indefinitely.

The warning was published Thursday, where the official count for coronavirus cases hit 220,000 infections around the world, with more than 10,000 cases in the United States alone.

Several countries have closed their borders and restricted travel to their citizens and residents in an effort to stem the spread of the virus.

This week, the European Union closed the so-called Schengen border which covers the 27 member state bloc, and the U.S. closed its border with Canada to all but essential travel and trade.

The pandemic has seen stocks and global financial markets tank, prompting governments to inject cash and slash interest rates to try to keep their economies afloat.


Source: Tech Crunch

Workers sent home after Amazon warehouse employee tests positive for COVID-19

It was, it seems, only a matter of time before something like this happened. As we noted in yesterday’s FreshDirect story, not everyone has the ability of being able to shelter in place during the spread of COVID-19. In fact, the more of us who stay put, the more strain we’re going to put on workers who play a role in getting products and supplies to our door. 

Amazon today confirmed that an employee in its Queens, NY fulfillment center has tested positive for the novel coronavirus. The company texted employees at the facility about the case yesterday. The text, obtained by The Atlantic reads, “We’re writing to let you know that a positive case of the coronavirus (COVID-19) was found at our facility today.”

It may be the first of its kind in the facility, but it almost certainly won’t be the last. Even as companies encourage workers to stay home at the first sign of sickness for both their benefit and that of customers, many will no doubt come to work. And then there’s the matter of those who are largely asymptomatic. 

We’ve reached out to Amazon to commitment on the incident. The company noted in the text that workers at the DBK1 facility were sent home, while the sorting facility was disinfected. Amazon has denied reports that, while dayshift workers were sent home, those on the night shift were still expected to come in.

In spite of the company’s massive footprint, Amazon has been forced to limit certain shipments, including non-essentials through its Fulfillment by Amazon program, along with the temporary pausing of shipments from Prime Pantry.


Source: Tech Crunch